Senses Disorder TRIZ Cases

Epothilone D resolves poor brain penetration and peripheral toxicity of paclitaxel by modifying its chemical structure to achieve selective retention.

Segmented T-cell independent antigens and TLR agonists activate B-cells directly, resolving vaccine ineffectiveness in immunocompromised patients.

Hyaluronan-binding domains fuse to therapeutic proteins, extending vitreous half-life without generating non-natural metabolites or adverse events.

Bis(nitrooxy) derivatives release nitric oxide to induce vessel relaxation.

Hydroxyl-terminated dendrimers covalently conjugate functional nucleic acids to enable selective intracellular delivery.

Alkyl ether piperazine derivatives achieve high sigma-1 receptor binding affinity while maintaining selectivity against sigma-2 receptors.

PRINT technology creates uniform implants that maintain therapeutic levels for months, reducing adverse events from repeated injections.

Complement factor B inhibitors reduce C3 deposits in eyes and kidneys, resolving tissue damage caused by dysregulated alternative pathway hyperactivity.

Novel compounds inhibit USP30 to rescue mitochondrial defects, enhancing mitophagic clearance and sensitizing cancer cells to apoptosis.

Histidine buffers and sorbitol maintain monomeric anti-C5 antibodies at high concentrations, preventing aggregation during storage.

Novel carboxylic acid substituted pyrrolidine compounds act as GPR40 modulators to promote glucose-stimulated insulin secretion.

Fluorescently labeled peptide substrates replace mechanical separation steps to measure Rpn11 cleavage rates via polarization changes.

Crystalline lipoic acid choline tosylate salts resolve hygroscopic handling issues while maintaining therapeutic efficacy in presbyopia treatments.

Formula I heterocyclic compounds lower blood retinol binding protein 4 to treat age-related macular degeneration and Stargardt's disease.

Segmented benzamide structures target Rho kinase to overcome limited therapeutic options in hypertension treatment.

Antibodies bind human angiopoietin-2 with unique CDR regions, blocking receptor interaction without affecting angiopoietin-1 to reduce tumor metastasis.

Viscoelastic medium fills scleral fistulae to prevent scar formation and sustain aqueous humour drainage.

Floating culture of pluripotent stem cell aggregates yields retinospheres enriched with ciliary marginal zone stem cells.

A compact gamma-synuclein promoter drives high-level transgene expression in retinal ganglion cells.

A periodic dosage regimen transiently reduces systemic immunosuppression to enhance leukocyte activity.

Anti-CD160 antibodies bypass VEGF resistance by inducing endothelial cell death, treating refractory neovascular eye diseases without associated side effects.

3-aryl-5-substituted-2H-isoquinolin-1-one compounds inhibit PARP and Wnt signaling pathways.

Selective CBP EP300 bromodomain inhibitors address off-target toxicity risks while improving therapeutic efficacy.

Peptidomimetic compounds cross the blood-brain barrier to activate neurotrophin receptors, addressing NGF delivery limitations.

A synthetic amyloid precursor protein signal peptide induces stem cell differentiation into nerve cells.

Quinazolone compounds regulate inflammatory markers to treat cardiovascular diseases without steroid side effects.

Novel bicyclic pyridine compounds modulate sirtuin protein activity to enhance mitochondrial function and extend cellular lifespan.

Gene expression profiling identifies specific biomarkers to distinguish atrial fibrillation from large artery stroke causes.

Subconjunctival corticosteroid-loaded liposomes provide sustained intracellular release to reduce drug loss from tear drainage and lower side effects.

Selected peptide combinations bind multiple HLA Class II alleles, resolving population coverage limits while reducing clinical development time.

Lipophilic prodrugs with positive charges overcome slow skin penetration to achieve faster plasma levels while reducing hepatotoxicity.

Segmented bioerodible implants use varying polymer blends to provide flexible release profiles, eliminating frequent injections and systemic side effects.

A preservative-free nanoemulsion formulation containing an alpha 2 adrenergic agonist enhances ocular bioavailability.

Sucrose and polysorbate 80 stabilize high-concentration anti-VEGF antibodies, preventing aggregation and sub-visible particle formation.

Asymmetric reduction establishes chiral centers in carboxamidine synthesis, resolving low stereoselectivity in FLAP inhibitor production.

Formula I compounds inhibit indoleamine 2,3-dioxygenase to restore tryptophan levels and enhance T-cell activation against cancer.

Enzymatic cleavage produces stable 10-60 kDa hyaluronic acid fragments that relieve pain and reduce fat without facial inflammation.

Synthesized indazole malonic acid salts react with base metal ions to form compounds with enhanced water solubility.

A ginseng berry extract composition relieves mental and physical exhaustion.

Novel heteroaromatic compounds inhibit the RORγ transcription factor to treat autoimmune disorders.

Exosome-based therapy avoids surgical complications by extracting therapeutic factors to treat ocular diseases.

Targeted recombinant human monoclonal antibodies neutralize JC and BK viruses by binding VP1, preventing reactivation without triggering inflammatory syndromes.

Low-temperature melt extrusion prevents heat-sensitive cyclic lipid degradation during implant fabrication, ensuring sustained therapeutic potency.

Neutralizing RGMa via specific antibodies addresses underlying degeneration progression beyond symptom management.

Segmented LPA antagonists treat fibrosis and cancer by reducing fibroblast recruitment.